Literature DB >> 1697729

Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations.

M L Carcangiu1, J T Chambers, I M Voynick, M Pirro, P E Schwartz.   

Abstract

A series of 183 cases of primary endometrial carcinomas were immunohistochemically stained for estrogen receptors (ERs) and progesterone receptors (PRs) using formalin-fixed, paraffin-embedded sections. All specimens were obtained from uterine curettages performed at the time of the initial diagnosis or initial therapy. The ER and PR content in the malignant and benign components (benign epithelium, stroma, and myometrium) was evaluated separately for positivity and divided into three groups according to the percentage of positive cells and the intensity of the nuclear stain. Endometrioid-type adenocarcinoma had the highest degree of positivity for both receptors, followed by adenosquamous carcinoma, serous carcinoma, and clear cell carcinoma. The positivity for ERs and PRs of the malignant component was statistically correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage (P less than 0.01), FIGO grade (P less than 0.001), and nuclear grade (P less than 0.0001) of the tumors. The degrees of ER and PR positivity of the malignant component correlated with each other (P less than 0.0001). There was no association between the depth of myometrial tumor invasion and either receptor status of the malignant component. There was a significant association between the presence of lymph vessel invasion and the positivity for PR. Positivity for PR correlated negatively with the patients' ages (P less than 0.004). The results of this study indicate that immunohistochemical analysis of sex steroid receptor status on formalin-fixed, paraffin-embedded tissue offers an excellent alternative to the standard biochemical procedure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697729     DOI: 10.1093/ajcp/94.3.247

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  19 in total

1.  Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium.

Authors:  Sema Bircan; Arzu Ensari; Sibel Ozturk; Nural Erdogan; Ilkkan Dundar; Firat Ortac
Journal:  Pathol Oncol Res       Date:  2005-03-31       Impact factor: 3.201

2.  Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status.

Authors:  M Koshiyama; I Konishi; D P Wang; M Mandai; T Komatsu; S Yamamoto; K Nanbu; M F Naito; T Mori
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

3.  Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas.

Authors:  Oluwole Fadare; Samuel James; Mohamed M Desouki; Dineo Khabele
Journal:  Ann Diagn Pathol       Date:  2013-05-21       Impact factor: 2.090

4.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.

Authors:  Oluwole Fadare; Wenxin Zheng; Marta A Crispens; Howard W Iii Jones; Dineo Khabele; Katja Gwin; Sharon X Liang; Khaled Mohammed; Mohamed M Desouki; Vinita Parkash; Jonathan L Hecht
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

5.  Progestin-releasing intrauterine device insertion plus palliative radiotherapy in frail, elderly uterine cancer patients unfit for radical treatment.

Authors:  Gabriella Macchia; Francesco Deodato; Savino Cilla; Francesco Legge; Vito Carone; Vito Chiantera; Vincenzo Valentini; Alessio Giuseppe Morganti; Gabriella Ferrandina
Journal:  Oncol Lett       Date:  2016-03-29       Impact factor: 2.967

6.  Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer.

Authors:  Houshiyar Ghafouri; Bayazid Ghaderi; Sabrieh Amini; Bahram Nikkhoo; Mohammad Abdi; Abdolhakim Hoseini
Journal:  Tumour Biol       Date:  2015-12-23

7.  Immunohistochemical Study of ER, PR, Ki67 and p53 in Endometrial Hyperplasias and Endometrial Carcinomas.

Authors:  Nayar Musfera Abdul Masjeed; Siddhi Gaurish Sinai Khandeparkar; Avinash R Joshi; Maithili Mandar Kulkarni; Nidhi Pandya
Journal:  J Clin Diagn Res       Date:  2017-08-01

8.  The EnDA endometrial adenocarcinoma: an oestrogen-sensitive, metastasizing, in vivo tumour model of the rat.

Authors:  D W Horn; G Vollmer; F Deerberg; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.

Authors:  Linda R Duska; Virginia L Filiaci; Joan L Walker; Laura L Holman; Emily K Hill; Richard G Moore; Kari L Ring; Michael L Pearl; Carolyn Y Muller; Christina L Kushnir; Heather A Lankes; Megan I Samuelson; Kelley S Carrick; Anand Rajan; William H Rodgers; Elise C Kohn; Richard Piekarz; Kimberly K Leslie
Journal:  Clin Cancer Res       Date:  2021-03-25       Impact factor: 12.531

10.  The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection.

Authors:  Can Guo; Zhi-Gang Pan; Da-Jiang Li; Jing-Ping Yun; Mei-Zhen Zheng; Zhe-Yu Hu; Li-Zhen Cheng; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2006-05-29       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.